Literature DB >> 25618799

Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study.

Yasuyo Wada1, Tadakazu Hisamatsu2, Makoto Naganuma3, Katsuyoshi Matsuoka4, Susumu Okamoto4, Nagamu Inoue3, Tomoharu Yajima4, Keisuke Kouyama5, Yasushi Iwao6, Haruhiko Ogata3, Toshifumi Hibi7, Takayuki Abe5, Takanori Kanai4.   

Abstract

BACKGROUND & AIM: Although inflammatory bowel disease (IBD) patients are at risk for metabolic bone disease, studies analyzing this correlation have identified various risk factors, including disease phenotype, age, sex and steroid therapy. Furthermore, few studies have assessed risk factors for bone loss in Japanese IBD patients. This study analyzed risk factors for metabolic bone disease in Japanese IBD patients.
METHODS: This cross-sectional study assessed 388 patients with IBD aged 20-50 years, including 232 with ulcerative colitis (UC) and 156 with Crohn's disease (CD). Bone mineral density of the femoral neck, total femur and lumbar spine was quantified by dual-energy X-ray absorptiometry. The blood concentrations of bone metabolism markers were measured. History of smoking and bone fracture, and nutritional intake were assessed using questionnaires.
RESULTS: Of the 388 patients with IBD, 78 (20.1%; UC, 17.2%; CD, 24.4%) had osteopenia and 17 (4.4%; UC, 3.4%; CD, 5.8%) had osteoporosis, as assessed by T-score. Bone mineral density of the lumbar vertebrae was lower in males than in females. Multivariate regression analysis showed that risk factors for bone loss in UC patients were male sex, low body mass index (BMI), high steroid dose and disease location. Risk factors for bone loss in CD patients were male sex and low BMI.
CONCLUSION: Among Japanese patients with IBD, male sex and low BMI were associated with increased risk for metabolic bone disease. In addition, Steroid therapy shouldn't be indiscriminate in UC patients. These findings may help identify patients at particularly high risk of metabolic bone disease and may help implement appropriate therapies in a timely manner and improve long-term quality of life.
Copyright © 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Body mass index; Crohn's disease; Inflammatory bowel disease; Japanese; Osteoporosis; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25618799     DOI: 10.1016/j.clnu.2015.01.003

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  5 in total

1.  Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis.

Authors:  Mirella Brasil Lopes; Andre Castro Lyra; Raquel Rocha; Fernanda Gomes Coqueiro; Carla Andrade Lima; Carolina Cunha de Oliveira; Genoile Oliveira Santana
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-07-05

2.  The Role of Monocyte Percentage in Osteoporosis in Male Rheumatic Diseases.

Authors:  Yu-Jih Su; Chao Tung Chen; Nai-Wen Tsai; Chih-Cheng Huang; Hung-Chen Wang; Chia-Te Kung; Wei-Che Lin; Ben-Chung Cheng; Chih-Min Su; Sheng-Yuan Hsiao; Cheng-Hsien Lu
Journal:  Am J Mens Health       Date:  2017-09-13

Review 3.  Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases.

Authors:  Alicja Ewa Ratajczak; Anna Maria Rychter; Agnieszka Zawada; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2020-06-06       Impact factor: 5.717

4.  Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing.

Authors:  Yu-Jih Su
Journal:  Clin Rheumatol       Date:  2020-05-28       Impact factor: 2.980

5.  Updated bone mineral density status in Saudi patients with inflammatory bowel disease.

Authors:  Mohammed Ewid; Nawaf Al Mutiri; Khalid Al Omar; Amal N Shamsan; Awais A Rathore; Nazmus Saquib; Anas Salaas; Omar Al Sarraj; Yaman Nasri; Ahmed Attal; Abdulrahman Tawfiq; Hossam Sherif
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.